Aspira Pathlab & Diagnostics

Aspira Pathlab & Diagnostics Equity

The The Equity of Aspira Pathlab & Diagnostics (540788.BO) as of Oct 11, 2026 is 121.66 M INR. In the previous year, The Equity was 101.43 M INR — a change of 19.95% (higher).

Equity

121.66 MINR

YoY

19.95%

Last updated:

In 2025, Aspira Pathlab & Diagnostics's equity was 121.66 M INR, a 19.95% increase from the 101.43 M INR equity in the previous year.

The Aspira Pathlab & Diagnostics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
3.35 M INR
Jan 1, 2019
51.91 M INR
Jan 1, 2020
38.01 M INR
Jan 1, 2021
83.15 M INR
Jan 1, 2022
127.90 M INR
Jan 1, 2023
127.50 M INR
Jan 1, 2024
101.43 M INR
Jan 1, 2025
121.66 M INR
The Aspira Pathlab & Diagnostics Equity history
YEAREquityYoY
121.66 MINR+19.95%
101.43 MINR-20.45%
127.50 MINR-0.31%
127.90 MINR+53.82%
83.15 MINR+118.75%
38.01 MINR-26.79%
51.91 MINR+1,450.53%
3.35 MINR-94.34%
59.16 MINR+62.63%
36.38 MINR+477.42%
6.30 MINR—
Access this data via the Eulerpool API
Get Free API Key

Aspira Pathlab & Diagnostics Stock analysis

What does Aspira Pathlab & Diagnostics do? Aspira Pathlab & Diagnostics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Aspira Pathlab & Diagnostics's Equity

Aspira Pathlab & Diagnostics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Aspira Pathlab & Diagnostics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Aspira Pathlab & Diagnostics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Aspira Pathlab & Diagnostics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Aspira Pathlab & Diagnostics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Aspira Pathlab & Diagnostics stock

The Equity of Aspira Pathlab & Diagnostics is 121.66 M INR in 2025.

The Equity of Aspira Pathlab & Diagnostics changed from 101.43 M INR to 121.66 M INR, representing a 19.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Aspira Pathlab & Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The Equity's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Aspira Pathlab & Diagnostics historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Aspira Pathlab & Diagnostics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Aspira Pathlab & Diagnostics